Xylan from corn cobs, a promising polymer for drug delivery: Production and characterization

Oliveira, Elquio Eleamen; Silva, Acarília Eduardo; Nagashima, Toshiyuki; Gomes, Monique Christine Salgado; Aguiar, Larissa Muratori; Marcelino, Henrique Rodrigues; Araújo, Ivonete Batista de; Bayer, Marc P.; Ricardo, Nágila M.P.S.; Oliveira, Anselmo Gomes de; Egito, Eryvaldo Sócrates Tabosa do

doi:10.1016/j.biortech.2010.01.137

Cited by 129 publications

(79 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Initially, the xylan infrared spectrum (Figure 4) was found to be similar to those reported by our group and elsewhere [12,21]. Concerning the FT-IR spectrum of PbMs, peaks ascribed for polysaccharides were also detected.…”

Section: Ft-ir Spectroscopysupporting

confidence: 84%

“…Dulbecco's modified eagle medium (DMEM) was obtained from Gibco (Gaithersburg, MD, USA). Xylan was obtained after extraction from corn cobs as previously described by our group [12].…”

Section: Methodsmentioning

confidence: 99%

“…As previously suggested by Oliveira and colleagues, the XRD analysis of xylan presented a profile of amorphous polymers displaying no crystallinity peaks. On the other hand, the cross-linking agent showed several peaks due to its crystallinity [12] (Figure 5a,b). In fact, the analysis of PbMs detected two peaks with different intensities near the angle for TC peaks [25].…”

Section: Xrd Analysismentioning

confidence: 99%

See 2 more Smart Citations

Leads from Physical, Chemical, and Thermal Characterization on Cytotoxic Effects of Xylan-Based Microparticles

et al. 2015

View full text Add to dashboard Cite

Interfacial cross-linking (ICL) has been considered a feasible technique to produce polysaccharide-based microparticles (PbMs), even though only a few studies have been concerned with their biocompatibility. In this work, PbMs were prepared by the ICL method and characterized in regard to their in vitro biocompatibility, chemical linkages, and physical and thermal properties. First, the cell viability assay revealed that PbMs toxicity was concentration-dependent. Then, it was observed that the toxicity may be related to the way in which the binding occurred, and not exclusively to the stoichiometry between the polymer and the cross-linking agent. Moreover, the PbMs biosafety was predicted by the use of physicochemical procedures, which were able to identify unbound cross-linking agent residues and also to reveal the improvement of their thermal stability. Accordingly, this work suggests a step-by-step physicochemical procedure able to predict potential toxicity from micro-structured devices produced by polysaccharides. Likewise, the use of PbMs as a drug carrier should be cautiously considered.

show abstract

Section: Ft-ir Spectroscopysupporting

confidence: 84%

“…Dulbecco's modified eagle medium (DMEM) was obtained from Gibco (Gaithersburg, MD, USA). Xylan was obtained after extraction from corn cobs as previously described by our group [12].…”

Section: Methodsmentioning

confidence: 99%

Section: Xrd Analysismentioning

confidence: 99%

See 1 more Smart Citation

Leads from Physical, Chemical, and Thermal Characterization on Cytotoxic Effects of Xylan-Based Microparticles

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Numerous studies use the xylan polymer as a specific substrate for xylanases. Besides that, xylan can be hydrolyzed into xylose and subsequently be converted into ethanol (Ebringerova & Heinze, 2000;Ebringerova et al, 1998;Garcia et al, 2000;Kayserilioglu et al, 2003;Oliveira et al, 2010;Sedlmeyer, 2011;Yang et al, 2005).…”

Section: Wwwintechopencommentioning

confidence: 99%

“…The wis-X has the ability to remain intact in the physiological stomach environment and small intestine. This property, together with the presence of xylanases (a group of enzymes which degrade the xylan) in the human colon, makes this polymer a suitable raw material for the medical field, especially as a constituent of colon-specific drug carriers (Oliveira et al, 2010;Rubinstein, 1995;Silva et al, 2007).…”

Section: Wwwintechopencommentioning

confidence: 99%